Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/111962
Title: Association of Systemic Medication Use with Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium
Authors: Vergroesen, Joëlle E.
Schuster, Alexander K.
Stuart, Kelsey V.
Asefa, Nigus G.
Cougnard-Grégoire, Audrey
Delcourt, Cécile
Schweitzer, Cédric
Barreto, Patrícia 
Coimbra, Rita 
Foster, Paul J.
Luben, Robert N.
Pfeiffer, Norbert
Stingl, Julia V.
Kirsten, Toralf
Rauscher, Franziska G.
Wirkner, Kerstin
Jansonius, Nomdo M.
Arnould, Louis
Creuzot-Garcher, Catherine P.
Stricker, Bruno H.
Keskini, Christina
Topouzis, Fotis
Bertelsen, Geir
Eggen, Anne E.
Bikbov, Mukharram M.
Jonas, Jost B.
Klaver, Caroline C. W.
Ramdas, Wishal D.
Khawaja, Anthony P.
Keywords: Epidemiology; Glaucoma; Intraocular pressure; Systemic medication
Issue Date: Sep-2023
Publisher: Elsevier
Serial title, monograph or event: Ophthalmology
Volume: 130
Issue: 9
Abstract: Purpose: To investigate the association of commonly used systemic medications with glaucoma and intraocular pressure (IOP) in the European population. Design: Meta-analysis of 11 population-based cohort studies of the European Eye Epidemiology Consortium. Participants: The glaucoma analyses included 143 240 participants and the IOP analyses included 47 177 participants. Methods: We examined associations of 4 categories of systemic medicationsdantihypertensive medications (b-blockers, diuretics, calcium channel blockers [CCBs], a-agonists, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers), lipid-lowering medications, antidepressants, and antidiabetic medicationsdwith glaucoma prevalence and IOP. Glaucoma ascertainment and IOP measurement method were according to individual study protocols. Results of multivariable regression analyses of each study were pooled using random effects meta-analyses. Associations with antidiabetic medications were examined in participants with diabetes only. Main Outcome Measures: Glaucoma prevalence and IOP. Results: In the meta-analyses of our maximally adjusted multivariable models, use of CCBs was associated with a higher prevalence of glaucoma (odds ratio [OR], 1.23; 95% confidence interval [CI], 1.08 to 1.39). This association was stronger for monotherapy of CCBs with direct cardiac effects (OR, 1.96; 95% CI, 1.23 to 3.12). No other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were associated with glaucoma. Use of systemic b-blockers was associated with a lower IOP (b coefficient, 0.33 mmHg; 95% CI, 0.57 to 0.08 mmHg). Monotherapy of both selective systemic b-blockers (b coefficient, 0.45 mmHg; 95% CI 0.74 to 0.16 mmHg) and nonselective systemic b-blockers (b coefficient, 0.54 mmHg; 95% CI, 0.94 to 0.15 mmHg) was associated with lower IOP. A suggestive association was found between use of high-ceiling diuretics and lower IOP (b coefficient, 0.30 mmHg; 95% CI, 0.47 to 0.14 mmHg) but not when used as monotherapy. No other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were associated with IOP. Conclusions: We identified a potentially harmful association between use of CCBs and glaucoma prevalence. Additionally, we observed and quantified the association of lower IOP with systemic b-blocker use. Both findings potentially are important, given that patients with glaucoma frequently use systemic antihypertensive medications. Determining causality of the CCB association should be a research priority.
URI: https://hdl.handle.net/10316/111962
ISSN: 01616420
DOI: 10.1016/j.ophtha.2023.05.001
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
I&D ICBR - Artigos em Revistas Internacionais

Files in This Item:
Show full item record

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons